1. Home
  2. YDKG vs MBIO Comparison

YDKG vs MBIO Comparison

Compare YDKG & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Yueda Digital Holding Class A Ordinary Share

YDKG

Yueda Digital Holding Class A Ordinary Share

HOLD

Current Price

$0.89

Market Cap

4.8M

ML Signal

HOLD

MBIO

Mustang Bio Inc.

HOLD

Current Price

$0.67

Market Cap

5.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YDKG
MBIO
Founded
2005
2015
Country
China
United States
Employees
17
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.8M
5.6M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
YDKG
MBIO
Price
$0.89
$0.67
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
138.5K
67.3K
Earning Date
05-12-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
98.99
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.02
$0.53
52 Week High
$3.90
$7.00

Technical Indicators

Market Signals
Indicator
YDKG
MBIO
Relative Strength Index (RSI) 47.17 43.84
Support Level $0.81 $0.58
Resistance Level $1.02 $0.82
Average True Range (ATR) 0.08 0.08
MACD 0.00 -0.00
Stochastic Oscillator 24.70 11.91

Price Performance

Historical Comparison
YDKG
MBIO

About YDKG Yueda Digital Holding Class A Ordinary Share

Yueda Digital Holding is a digital-economy company with a focus on the long-term accumulation of mainstream cryptocurrencies. The business activities of the company include active treasury management of mainstream digital assets, exploration of compliant, risk-managed yield opportunities, such as staking, on-chain liquidity provision, and other conservative market activities, selective investments and partnerships in Web3 infrastructure and applications, and advisory services for enterprises entering the digital-asset economy.

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Share on Social Networks: